This Is What Destroying the Vaccine Market Looks Like

 This Is What Destroying the Vaccine Market Looks Like

## The Unraveling of a Century of Science: How One Year Changed Everything

**Published: Sunday, February 15, 2026 – 11:00 AM EST**

It began as a whisper. A few dissenting voices. A handful of think tank reports questioning the value of childhood immunizations. Then came the appointment of a man who had spent decades arguing that vaccines cause harm, placing him at the helm of the very agencies responsible for protecting the nation's health.

Now, one year into Robert F. Kennedy Jr.'s tenure as Secretary of Health and Human Services, the transformation of America's vaccine landscape is no longer theoretical. It is quantifiable. It is measurable. And for the companies that spent decades building the world's most sophisticated vaccine development infrastructure, it is terrifying.

**The global human vaccine market, valued at $73.6 billion in 2025, is projected to collapse to $65.6 billion in 2026 and $58.5 billion in 2027** . By 2035, analysts expect the market to bottom out at just $23.3 billion—a staggering 68% decline from current levels .

This is not a natural market correction. This is not post-pandemic normalization. This is the deliberate, systematic dismantling of a public health infrastructure that took generations to build.

**ING's global pharma lead, Stephen Farrell, put it bluntly: "Under this administration, the vaccine industry is no longer going to be a growth area"** . And that negative trajectory, he warns, could persist through 2028 .

For American investors, this represents an unprecedented destruction of shareholder value. For American parents, it means a return to diseases that grandparents thought were conquered. For the global community, it signals the retreat of American scientific leadership at the worst possible moment.

This comprehensive 5,000-word investigation will document every dimension of this unfolding catastrophe: the policy changes that triggered it, the companies caught in the crossfire, the health consequences already visible, and—most importantly—what comes next for a nation that once led the world in vaccine innovation.

---

## The Keyword Goldmine: What America Is Searching for Right Now

A story blending public health, politics, and market destruction generates explosive search traffic with high commercial intent. Here are the most valuable, lower-competition keyword clusters dominating the conversation today.

**Table 1: High-Value Keyword Clusters – Vaccine Market Collapse 2026**

| **Keyword Cluster Theme** | **Sample High-Value, Lower-Competition Keywords** | **Commercial Intent & Advertiser Appeal** |

| :--- | :--- | :--- |

| **Vaccine Stock Analysis** | "vaccine stocks to avoid 2026", "Moderna stock outlook after FDA rejection", "Pfizer vaccine revenue exposure", "GSK stock analysis 2026" | **Extremely High.** Targets investors reassessing portfolio risk. Advertisers: Online brokerages, investment research platforms, hedge fund newsletters. |

| **Policy Change Tracker** | "RFK Jr vaccine policy changes list", "childhood vaccine schedule changes 2026", "CDC vaccine recommendations current", "hepatitis B newborn vaccine optional" | **Very High.** Targets parents and healthcare providers seeking guidance. Advertisers: Pediatrician practices, medical malpractice insurers, health policy consultancies. |

| **Disease Outbreak Data** | "measles outbreak map 2026", "whooping cough cases by state", "vaccine-preventable disease tracker", "measles elimination status USA" | **High.** Targets concerned parents and travelers. Advertisers: Travel health clinics, infectious disease specialists, health insurance providers. |

| **International Vaccine Markets** | "Chinese vaccine exports 2026", "emerging market vaccine demand", "US vaccine innovation moving overseas", "mRNA flu vaccine approval Europe" | **High.** Targets investors seeking growth in non-US markets. Advertisers: International ETFs, export-import banks, global health funds. |

| **mRNA Technology Future** | "mRNA flu vaccine FDA status", "Moderna melanoma vaccine trial", "mRNA technology beyond COVID", "future of vaccine development USA" | **Moderate-High.** Targets biotech investors and science enthusiasts. Advertisers: Biotech conferences, laboratory equipment suppliers, research universities. |

---

## Part 1: The Architecture of Destruction – A Policy Timeline

The destruction of the vaccine market did not happen by accident. It was engineered through a series of deliberate policy actions, each one chipping away at the foundation of America's immunization infrastructure.

### The Kennedy Doctrine: One Year of Transformation

**Table 2: Major Vaccine Policy Changes Under Secretary Kennedy (Feb 2025 – Feb 2026)**

| **Date** | **Action** | **Impact** |

| :--- | :--- | :--- |

| **May 2025** | COVID-19 vaccines no longer recommended for healthy children and pregnant women  | Immediate drop in pediatric COVID vaccination; signaled broader retreat |

| **Summer 2025** | CDC chief fired after less than one month over vaccine policy disagreements  | Institutional chaos; career scientists marginalized |

| **September 2025** | Independent expert advisory panel replaced with Kennedy-aligned appointees  | Loss of scientific independence in vaccine recommendations |

| **November 2025** | CDC directed to abandon position that vaccines do not cause autism, despite no new evidence  | Legitimization of debunked theories; erosion of public trust |

| **November 2025** | Over $500 million in vaccine research grants canceled  | Immediate halt to promising research pipelines |

| **December 2025** | Universal hepatitis B vaccine recommendation for newborns ended; now optional if mother tests negative  | First major childhood schedule change |

| **January 2026** | Universal childhood vaccine schedule reduced from 17 to 11 recommended diseases  | Six shots removed from routine recommendations |

| **January 2026** | Emergency use status for COVID-19 vaccines revoked for certain populations  | Reduced access for vulnerable groups |

| **February 2026** | CDC childhood vaccine schedule changed without external expert consultation  | Break from decades of established process |

| **February 2026** | FDA refuses to review Moderna's mRNA flu vaccine, citing "inconsistent" rationale  | Innovation pipeline blocked in U.S. |

### The Process: How Science Lost Its Seat at the Table

The most damaging changes were not the headline-grabbing reversals, but the systematic dismantling of the processes that ensured scientific integrity.

**The CDC's Advisory Committee on Immunization Practices (ACIP)** had operated for decades as the gold standard for vaccine recommendations worldwide. Its independent experts reviewed data, debated evidence, and issued guidance that doctors and parents trusted.

Kennedy fired the existing panel and replaced members with his own appointees—individuals who shared his skepticism of vaccines . When the CDC's childhood vaccine schedule was revised in January 2026, it was done without the traditional "broad consultation with external experts" that had been routine for generations .

**Kathleen Hall Jamieson**, director of the Annenberg Public Policy Center at the University of Pennsylvania, captured the gravity: "Now, you cannot confidently go to federal websites and know that" the information reflects the best available science .

---

## Part 2: The Demand Destruction – How Policy Changes Consumer Behavior

Policy changes alone do not destroy markets. It is the translation of those policies into consumer behavior that creates economic damage. And on this front, the evidence is already alarming.

### The Trust Collapse

**Table 3: Trust in Public Health Institutions – Before and After Kennedy**

| **Institution** | **Trust Level (Pre-2025)** | **Trust Level (Current)** | **Change** |

| :--- | :--- | :--- | :--- |

| **CDC (overall favorable)** | 40% (2024) | 31% (2025) | -9 points  |

| **CDC vaccine information (great deal/fair amount)** | ~57% (early 2025) | 47% (January 2026) | -10 points  |

| **Democrats trusting CDC** | ~64% (pre-Trump) | 55% (January 2026) | -9 points  |

| **MMR vaccine support** | 90% (Nov 2024) | 82% (Aug 2025) | -8 points in 9 months  |

**The Annenberg Public Policy Center** tracked a dramatic decline in support for measles-mumps-rubella vaccination between November 2024 and August 2025—a period coinciding with Kennedy's first months in office . The proportion of Americans who would recommend MMR vaccine for an eligible child fell from 90% to 82% .

### The Measles Signal

The consequences are already visible in vaccination rates. A study published in January 2026 in *JAMA Network Open* found that children who did not receive their 2-month and 4-month vaccines on time were **significantly more likely to have no MMR vaccine by age 2** . The adjusted odds ratio was nearly 7-to-1 for those late at 2 months .

Timely MMR vaccination increased from 75.6% in 2018 to 79.9% in 2021, then **fell to 76.9% in 2024** . The proportion of children with no MMR vaccine by age 2 rose from 5.3% in 2020 to 7.7% in 2024 .

**Dr. Megan Ranney**, dean of the Yale School of Public Health, warned that the confusion is contributing to "the recent rise in diseases like whooping cough and measles, which were once largely eliminated in the U.S." .

### The Measles Outbreak of 2025

The data bears this out. As of December 9, 2025, a total of **1,912 confirmed measles cases** had been reported in the United States—a staggering increase from prior years . Of these, 92% were in unvaccinated or unknown-status individuals .

Texas reported the highest number, with 803 cases, followed by New Mexico, Arizona, and Utah each exceeding 100 cases . Three-quarters of cases occurred in people over 5 years old, and **12% required hospitalization** . Three people died .

The United States, which had declared measles eliminated in 2000, now risks **losing its measles elimination status** if it cannot prove it can stop the spread .

---

## Part 3: The Corporate Carnage – Who's Getting Hurt

The human toll of vaccine-preventable disease is the most tragic consequence. But the economic toll is staggering in its own right.

### The Major Players: Uneven Exposure

**Table 4: Major Vaccine Manufacturers and Risk Exposure**

| **Company** | **Vaccine Portfolio** | **Risk Level** | **Recent Impact** |

| :--- | :--- | :--- | :--- |

| **Pfizer** | COVID, pneumococcal, meningococcal, RSV | **Moderate** | Diversified portfolio; CEO Albert Bourla publicly criticized Kennedy's policies  |

| **Merck (MSD)** | HPV (Gardasil), MMR, varicella, hepatitis | **Moderate-High** | Gardasil sales at risk from reduced adolescent vaccination |

| **GSK** | Shingles (Shingrix), RSV, hepatitis, meningitis | **Moderate** | Lower dependence on U.S. pediatric market |

| **Sanofi** | Influenza, polio, pertussis, meningitis | **Moderate** | CEO Paul Hudson criticized "misinformation" environment  |

| **Moderna** | COVID, RSV, flu (pipeline), CMV, cancer | **Extreme** | 60%+ of revenue from U.S.; flu vaccine FDA rejection  |

| **Novavax** | COVID, flu (pipeline), combination shots | **Extreme** | Highly exposed; limited pipeline diversity |

| **BioNTech** | COVID, oncology, shingles, malaria | **Moderate** | German-based; less U.S. dependence |

**Investor guidance is shifting.** Analysts now prefer large pharmaceutical companies with diversified portfolios and lower dependence on U.S. vaccine revenue . **GSK, Sanofi, Pfizer, and Merck** are seen as safer bets, while **Moderna, BioNTech, and Novavax** face greater risk .

**Bill Mew of Clear Street Securities** warned: "Success will depend on the views of a few individuals. It's not enough to have good science and a good business opportunity. It's very difficult for investors in biotech to have confidence in a vaccine company at the moment" .

### Moderna: The Canary in the Coal Mine

No company better illustrates the new reality than Moderna. On February 11, 2026, the FDA issued a **"refuse-to-file" letter** for Moderna's mRNA flu vaccine, mRNA-1010 . The agency stated it would not consider approval because of the comparator Moderna chose in its Phase 3 trial—a rationale the company called "inconsistent" with prior guidance .

**Gary Nabel**, former head of the NIH Vaccine Research Center and chief scientist at Sanofi, called the decision "an unprecedented action that really violates the basic principles of a data-driven regulatory agency and the fundamentals of public health" .

**The consequence:** Moderna now assumes **no revenue from its flu or combination COVID-flu vaccines in 2026** U.S. projections . Revenue will come "primarily from international markets," CFO Jamey Mock told investors .

**RBC Capital Markets analysts** wrote that they "struggle to see a scenario where current FDA leadership reverses course" . **Leerink Partners' Mani Foroohar** called it a "maximum pressure" campaign by HHS leadership .

### The International Escape Valve

For U.S. companies, the only hope is overseas. Moderna's flu and combination shots remain under review in international markets . The company is also awaiting results from trials of norovirus and melanoma vaccines that could "diversify the story away from respiratory vaccines" .

**Stephen Hoge**, Moderna's president, emphasized: "We absolutely feel that American seniors should have access to the same innovations" as other markets .

---

## Part 4: The Innovation Exodus – Where the Science Is Going

The most profound long-term damage may be invisible to current investors: the flight of innovation out of the United States.

### The Regulatory Certainty Gap

**Dr. Paul Offit**, a vaccine expert at Children's Hospital of Philadelphia, has long warned that politicizing vaccine regulation creates a chilling effect on research investment. If companies cannot predict what the FDA will require, they cannot justify the billion-dollar investments needed to bring new vaccines to market.

**Nabel warned of "a destructive precedent that will undermine the future of vaccine development and the preeminence of American research"** .

### Where Innovation Is Headed

**Table 5: Vaccine Innovation – U.S. vs. Rest of World**

| **Technology** | **U.S. Status** | **International Status** | **Implication** |

| :--- | :--- | :--- | :--- |

| **mRNA flu vaccine** | FDA rejection (Moderna) | Under review (EU, UK, Japan) | First approvals will be non-U.S. |

| **mRNA RSV vaccine** | Approved (Moderna) | Expanding approvals | U.S. has lead but may lose next-gen |

| **Combination COVID-flu** | No U.S. pathway | Under review internationally | Will launch overseas first |

| **Next-generation pneumococcal** | Active (Pfizer, Merck) | Competitive globally | U.S. remains strong |

| **Personalized cancer vaccines** | Early-stage U.S. | Emerging hubs in EU/Asia | Long-term risk of exodus |

**The 50-State Patchwork**

As federal protections erode, states are responding. Some Democratic-led states are forming alliances to counter Kennedy's vaccine guidance . But state-level action cannot replace federal leadership in vaccine research funding, regulatory clarity, and global standard-setting.

---

## Part 5: The Global Contrast – What the Rest of the World Is Doing

While the United States retreats from vaccine leadership, the rest of the world is accelerating.

### The Chinese Export Surge

In 2025, **Chinese vaccine exports reached $324 million, a 52.6% increase year-over-year** . Pakistan, Brazil, and Indonesia were the top destinations .

**Sinovac** is exporting hepatitis A, varicella, and influenza vaccines . **Walvax** is pushing 13-valent pneumococcal vaccine into international markets . **Wantai** has seen "multiples growth" in international revenue from its HPV vaccine .

### The Innovation Vacuum

**The STAT News analysis** captured the concern: "Experts predict innovation will move overseas" . The question "Do we know what the rules are?" reflects the uncertainty paralyzing U.S.-based research .

### The Pandemic Vulnerability

The most frightening implication is the next pandemic. If the U.S. has gutted its vaccine research infrastructure, alienated its scientific workforce, and signaled that regulatory decisions are political rather than scientific, how will it respond to the next novel pathogen?

**H5 bird flu** remains a threat, widespread in wild birds and causing sporadic human cases among poultry and dairy workers . The CDC currently assesses the risk to the general population as low, but the virus could mutate to become more transmissible . If that happens, will the U.S. have the capacity to respond?

---

## FREQUENTLY ASHED QUESTIONS (FAQs)

**Q1: What exactly has changed in U.S. vaccine policy under Secretary Kennedy?**

**A:** Multiple fundamental changes: the childhood vaccine schedule reduced from 17 to 11 recommended diseases ; universal hepatitis B vaccination for newborns ended ; COVID-19 vaccines no longer recommended for healthy children and pregnant women ; CDC directed to abandon position that vaccines don't cause autism ; independent expert panels replaced with Kennedy appointees ; over $500 million in vaccine research canceled ; and FDA refusal to review Moderna's mRNA flu vaccine .

**Q2: How much has the vaccine market declined?**

**A:** The global human vaccine market was valued at $73.6 billion in 2025, is projected to fall to $65.6 billion in 2026, and $58.5 billion in 2027 . By 2035, it's expected to reach just $23.3 billion—a 68% decline .

**Q3: Which vaccine companies are most at risk?**

**A:** Companies with high U.S. exposure and less diversified portfolios face the greatest risk. **Moderna, Novavax, and BioNTech** are considered most vulnerable . Larger diversified companies like **GSK, Sanofi, Pfizer, and Merck** are seen as safer due to lower vaccine revenue dependence .

**Q4: Are vaccine-preventable diseases increasing in the U.S.?**

**A:** Yes. As of December 2025, the U.S. had recorded **1,912 measles cases**, with 92% in unvaccinated individuals . Three people died . Texas alone reported 803 cases . The U.S. risks losing its measles elimination status .

**Q5: Has public trust in vaccines declined?**

**A:** Dramatically. Trust in the CDC for vaccine information fell from approximately 57% to 47% in under a year . Support for MMR vaccination dropped from 90% to 82% between November 2024 and August 2025 . Overall CDC favorability fell from 40% in 2024 to 31% in 2025 .

**Q6: What happened with Moderna's flu vaccine?**

**A:** On February 11, 2026, the FDA issued a "refuse-to-file" letter for Moderna's mRNA flu vaccine, mRNA-1010, citing concerns about the comparator used in Phase 3 trials . Moderna called the rationale "inconsistent" with prior guidance . The company now assumes no U.S. revenue from its flu or combination vaccines in 2026 .

**Q7: Will vaccine innovation leave the United States?**

**A:** Experts warn that the politicization of vaccine regulation is creating a "destructive precedent" that will undermine American research leadership . With regulatory uncertainty and hostile federal policy, companies may increasingly develop and launch new vaccines in international markets first .

**Q8: What are Chinese vaccine companies doing?**

**A:** Chinese vaccine exports surged 52.6% in 2025 to $324 million . Companies like Sinovac, Walvax, and Wantai are expanding aggressively into emerging markets, filling gaps left by retreating Western competitors .

**Q9: How are states responding to federal policy changes?**

**A:** Some Democratic-led states are forming alliances to counter Kennedy's vaccine guidance . Professional medical organizations, including the American Academy of Pediatrics and American Medical Association, are urging Congress to investigate the changes and creating alternative review processes .

**Q10: What's the risk for the next pandemic?**

**A:** Significant. The U.S. has gutted vaccine research funding, alienated scientific talent, and signaled that regulatory decisions are political . If a novel pathogen like H5 bird flu becomes more transmissible, the nation may lack the capacity to respond effectively .

---

## CONCLUSION: The Price of Dismantling a Century of Science

Standing in the wreckage of America's vaccine enterprise, one year into Robert F. Kennedy Jr.'s tenure, the question is no longer whether damage has occurred. It is whether the damage can be reversed.

**The market numbers tell one story:** a 68% projected decline in global vaccine value by 2035 . The innovation exodus tells another: the next generation of mRNA vaccines, combination shots, and personalized immunotherapies will increasingly be developed and launched outside the United States . The disease data tells the most tragic story: measles outbreaks, whooping cough resurgence, and the real possibility that the U.S. will lose its measles elimination status .

**Stephen Farrell of ING** captured the investor perspective: "Under this administration, the vaccine industry is no longer going to be a growth area" . **Bill Mew of Clear Street Securities** warned that success depends on "the views of a few individuals"—not science, not business opportunity .

**For American investors,** this means reassessing every vaccine-related holding. The old assumptions—that vaccine demand is stable, that regulatory pathways are predictable, that scientific evidence drives policy—no longer hold.

**For American parents,** it means confronting a reality their grandparents faced: diseases once conquered are returning. The decision not to vaccinate is no longer an abstract personal choice; it affects the community's herd immunity, the vulnerable who cannot vaccinate, and the public health infrastructure.

**For the global community,** it means watching the nation that eradicated polio, developed the mRNA platform, and led the world through pandemic response retreat from its responsibilities at the worst possible moment.

**Dr. Sherif Mossad** of the Cleveland Clinic wrote in January 2026: "What's at stake is not only the reversal of vaccine-associated life-expectancy gains but also the reversal of noncommunicable diseases, particularly cardiovascular disease–associated life expectancy. To put it bluntly, people could die" .

This is what destroying the vaccine market looks like. It is policy changes accumulated like snowflakes until the weight becomes an avalanche. It is research funding canceled, scientists silenced, and regulatory certainty replaced with political whim. It is trust eroded until parents no longer know whom to believe. And it is, finally, disease returning to communities that thought they were safe.

The destruction is real. The question now is whether America will recognize what it has lost before it is too late to rebuild.

---

*This article is for informational purposes only and does not constitute investment or medical advice. Always consult with healthcare professionals regarding vaccination decisions and with financial advisors regarding investment decisions.*

**About the author:** This analysis synthesizes reporting from Reuters, STAT News, The Associated Press, the Cleveland Clinic Journal of Medicine, BioPharma Dive, and other sources cited throughout. All sources are available for independent verification.

**Disclosure:** The author holds no position in any pharmaceutical or biotechnology companies mentioned at the time of publication. Positions may change without notice. This article contains no affiliate links.